Ruben van Eijk

@rpavaneijk

MND researcher | MD | PhD | Epidemiologist | Parttime cyclist

Vrijeme pridruživanja: siječanj 2018.

Tweetovi

Blokirali ste korisnika/cu @rpavaneijk

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @rpavaneijk

  1. proslijedio/la je Tweet

    Come and join us in Brisbane . Level up on your mad science skills, and meet new friends while searching for a cure for . Fully funded available 🐭 🧫 👤 - contact me s.ngo@uq.edu.au

    Poništi
  2. 6. pro 2019.

    What a great end of an excellent meeting by receiving the MND Clinical Poster prize for optimizing the use of the ALSFRS-R! The time may have come to say goodbye to the total score and make better use of its domain information in clinical trials.

    Poništi
  3. proslijedio/la je Tweet
    5. pro 2019.
    Poništi
  4. 5. pro 2019.

    Last day already of an enlightening MNDA Symposium, excellent talk by about the importance of hypermetabolism and appetite loss in patients with ALS. Superb graphs.

    Poništi
  5. proslijedio/la je Tweet
    4. pro 2019.

    What a great idea. would like people to donate their T-shirts to make a quilt. This will be raffled to support the fellows program. Hand shirts into rego desk if keen to contribute 🙌🙌🙌

    Poništi
  6. 3. pro 2019.

    Tofersen as promising therapeutic option for ALS. Results from phase 1 show treatment is safe and tolerable. Responder/non-responder analysis should be interpreted with caution. Interesting decline in neurofilament and late stage clinical trial is indicated

    Poništi
  7. 3. pro 2019.

    Many interesting talks about innovations in clinical trial design evaluating multiple treatments simultaneously, PET-based pharmacodynamic markers and promising therapeutic strategies using stem cells and antisense oligonucleotides

    Poništi
  8. 3. pro 2019.

    Excellent overview of biomarkers for MND by prof. Turner. Biomarkers can be very useful for multiple aspects of clinical trials, important to distinguish between the different aims: diagnostic, prognostic, predictive, pharmacodynamic and/or surrogate purposes

    Poništi
  9. 3. pro 2019.

    Most original start of the MNDA Symposium so far, looking forward to a great meeting!

    Poništi
  10. proslijedio/la je Tweet
    3. pro 2019.

    Hopes of minimising burden for patients as much as possible collaborative road map to best harness technology to improve the delivery of care & clinical trials for people with MND/ALS. How to best integrate and implement

    Poništi
  11. 2. pro 2019.

    Interesting discussion at about plateaus in ALSFRS-r decline, they are common and may occur already early in the disease and in trial populations. Should we still keep using the ALSFRS-R in clinical trials?

    Poništi
  12. 2. pro 2019.

    Great way to start the MNDA Symposium with the WFN satellite meeting about clinical trials, treatments for familial als, new biomarkers and outcome measures

    Poništi
  13. proslijedio/la je Tweet
    7. stu 2019.

    Excellent meeting in Utrecht organised by and colleagues to launch the initiative, paving the way for more efficient and more effective trials in Europe. Great to see so much industry interest!

    Poništi
  14. proslijedio/la je Tweet
    12. lis 2019.

    1ST for mankind this morning- sub 2hr marathon 1:59:40 amazing Kenyan

    Poništi
  15. 3. lis 2019.

    Great effort and very valuable to read the patient's opinion about trial participation, these kind of data can help significantly to design better clinical trials in the near future!

    Poništi
  16. proslijedio/la je Tweet
    Poništi
  17. proslijedio/la je Tweet
    6. ruj 2019.

    the authoritative guide to clinical trials for ALS just arrived in the post. Thanks and congratulations

    Poništi
  18. proslijedio/la je Tweet

    Good illustration of progress in cancer control, albeit with some notable exceptions.

    Poništi
  19. 23. kol 2019.

    The end of an era: PhD thesis approved and printed, defense is September 17th in Utrecht! I would like to thank all who contributed, especially and . Hope this thesis shortens the road towards a cure for

    Poništi
  20. proslijedio/la je Tweet
    31. srp 2019.

    Clinical trials in could be made more efficient with some simple changes, such as extending follow-up for patients enrolled early. Our tool to help improve trial design is here: and the paper describing our findings here:

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·